Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 1/31/2026

HPV Vaccination Schedule and Recommendations for Initiation at Age ≥ 15 years

Dosing Schedule for Individuals ≥ 15 years

  • For individuals aged 15 years or older who start the HPV vaccine series, a three‑dose schedule is required, with the second dose given 1–2 months after the first and the third dose 6 months after the first dose. 1, 2

Specific Dosing Intervals

  • The recommended timing for the three‑dose series in an 18‑year‑old (or any person ≥15 years) is:
    • Dose 1 – Day 0
    • Dose 2 – Approximately 2 months after Dose 1 (minimum interval 4 weeks)
    • Dose 3 – 6 months after Dose 1 (minimum interval 12 weeks from Dose 2)
      1, 2

Catch‑Up Vaccination (Through Age 26)

  • The Advisory Committee on Immunization Practices (ACIP) recommends catch‑up HPV vaccination for all persons up to 26 years of age who have not completed the series, regardless of prior vaccination status. 1, 2, 3

Pre‑Vaccination Testing Not Required

  • No laboratory or cytology testing is needed before starting the HPV vaccine series; Pap testing, HPV DNA testing, and HPV antibody testing are unnecessary. 1, 2, 3

Sexual Activity Does Not Alter Recommendation

  • Whether an individual is sexually active or has prior infection with one or more HPV types does not change the recommendation; vaccination still protects against HPV types not yet acquired. 1, 2

Management of Interrupted Schedules

  • If the vaccination series is interrupted, the series does not need to be restarted; remaining doses should be given while respecting the minimum intervals (≥4 weeks between Dose 1 and Dose 2, ≥12 weeks between Dose 2 and Dose 3). 1, 2

Common Pitfalls to Avoid

  • Two‑dose schedule applies only to those who begin vaccination before age 15; individuals starting at age 15 or older must receive three doses. 1, 2
  • Do not order pre‑vaccination screening tests (Pap, HPV DNA, antibody assays) as they add cost and delay without clinical benefit. 1, 2
  • Do not delay vaccination based on sexual history; the vaccine provides benefit even to sexually active individuals. 1, 2